Approved for people as young as four years old

Learn More

VNS Therapy is the first and only FDA-approved device for drug-resistant epilepsy that is clinically proven safe and effective for people as young as 4 years of age

Seizures can hold every child back from their full potential

Every day, 30 children will begin to have seizures that cannot be controlled with medication alone

Day after day, many children face the consequences of seizures4

Early use of VNS Therapy offers proven long-term outcomes for children at a critical time in their development5

VNS Therapy can lead to improved wellness by reducing health-related events4

Post-VNS Therapy Reductions


While on VNS Therapy, 2/3 of children taking benzodiazephines withdrew completely6

Proven safety and tolerability

Nonpharmacological side effect profile

  • Typically only during stimulation and generally diminish over time7,8
  • May be diminished or eliminated by the adjustment of parameter settings7,9

Incidence of adverse events following stimulation (>5%) were dysphonia, convulsion, headache, oropharyngeal pain, depression, dysphagia, dyspnea, dyspnea exertional, stress, and vomiting

With the latest VNS Therapy technology* MRI is now more accessible than ever

  • Your patients with VNS Therapy will have access to more than 7000 MRI centers around the country
  • Patients will find an MRI center within an average distance of 4 miles from your office
  • 100% access to brain MRI
  • Access to 90% of all MRI scans performed on people with epilepsy

* AspireHC model 105, AspireSR model 106


Find out more about scan conditions for all VNS Therapy models

Learn More

Review the most current labeling prior to performing an MRI Scan. For MRI safety information, refer to
MRI Instructions For Use

References

  1. US Census Bureau, www.census.gov/quickfacts/table/PST045216/00, accessed 05/22/2017
  2. Wirrell EC et al. Epilespy Res. 2011 June; 95(1-2):110-118.
  3. Mohanraj R et al. Eur J Neurology. 2006; 13:277-282.
  4. Helmers SL et al. Eur J of Paed Neuro. 2012; 16(5):449-458.
  5. Englot DJ et al. NeurosurgClin N Am. 2011; 22:443-448.
  6. Majkowska-Zwolinska B et al. Child Nerv Syst. 2012; 28:621-628.
  7. Ben-Menachem E. Journal of Clinical Neurophysiology. 2001; 18(5):415-418.
  8. Morris GL et al. Neurology. 1999; 53(8):1731-1735.
  9. Heck C et al. Neurology. 2002; 59(6 Suppl 4):S31-37.

Indication for Use
The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications.

Learn more about VNS Therapy

Visit VNSTherapy.com
 

Important Safety Information

P: 888-867-7846 • F: 281-218-9332 • 100 Cyberonics Boulevard • Houston, TX USA 77058
© LivaNova, Inc. 2016 | All rights reserved.